Bourgeoning Cancer Targets

Area of Science:

• Genomics and Oncology
• Cancer Biology
• Therapeutic Target Discovery

Background:

• Cancer genome identification has advanced understanding of tumor biology and therapeutic strategies.
• However, many cancer cell characteristics extend beyond genomic alterations, limiting the clinical impact of tumor genome characterization for numerous patients.
• There is a need for strategies that elucidate the circuitry and function of cancer genes, addressing both oncogene and non-oncogene deficiencies.

Approach:

• This review discusses a framework for identifying and categorizing a wide array of cancer targets.
• It explores emerging techniques that highlight the significance of non-oncogene deficiencies.
• The review synthesizes current knowledge on diverse therapeutic targets, including synthetic lethal targets, oncogene dependencies, DNA damage responses, tumor suppressor restoration, metabolic vulnerabilities, protein-protein interactions, master regulators, and immunomodulatory approaches.

Key Points:

• Therapeutic targets derived from non-oncogene deficiencies are potentially more extensive than those from mutated genes.
• A comprehensive framework is presented, encompassing various cancer target categories.
• These targets offer innovative prospects for clinical translation in cancer therapy.

Conclusions:

• Characterizing cancer genomes is crucial but insufficient for treating all patients, as cancer biology encompasses non-genomic features.
• Focusing on non-oncogene deficiencies and a broader range of targets presents a more expansive therapeutic landscape.
• The discussed targets hold significant promise for advancing clinical cancer treatment strategies.